

Committee on Energy and Commerce
U.S. House of Representatives
Witness Disclosure Requirement - "Truth in Testimony"
Required by House Rule XI, Clause 2(g)(5)

1. Your Name: Nathan Fountain		
2. Your Title: Chair, Epilepsy Foundation Professional Advisory Board		
3. The Entity(ies) You are Representing: Epilepsy Foundation		
4. Are you testifying on behalf of the Federal, or a State or local government entity?	Yes	No X
5. Please list any Federal grants or contracts, or contracts or payments originating with a foreign government, that you or the entity(ies) you represent have received on or after January 1, 2013. Only grants, contracts, or payments related to the subject matter of the hearing must be listed. Not applicable.		
6. Please attach your curriculum vitae to your completed disclosure form.		

Signature: _____



Date: 1/23/2015

INSTRUCTIONS FOR COMPLETING THE TRUTH-IN-TESTIMONY DISCLOSURE FORM

In General. The attached form is intended to assist witnesses appearing before the Committee on Energy and Commerce in complying with Rule XI, clause 2(g)(5) of the Rules of the House of Representatives, which provides:

(B) In the case of a witness appearing in a nongovernmental capacity, a written statement of proposed testimony shall include a curriculum vitae and a disclosure of any Federal grants or contracts, or contracts or payments originating with a foreign government, received during the current calendar year or either of the two previous calendar years by the witness or by an entity represented by the witness and related to the subject matter of the hearing. (C) The disclosure referred to in subdivision (B) shall include (i) the amount and source of each Federal grant (or subgrant thereof) or contract (or subcontract thereof) related to the subject matter of the hearing; and (ii) the amount and country of origin of any payment or contract related to the subject matter of the hearing originating with a foreign government. (D) Such statements, with appropriate redactions to protect the privacy or security of the witness, shall be made publicly available in electronic form not later than one day after the witness appears.

Please complete the form in accordance with these directions.

1. ***Name, Title, Entity(ies) (Items 1-3 on the form).*** Please provide the name and title of the witness and the entity(ies) on whose behalf the witness is testifying.
2. ***Governmental Entity (Item 4).*** Please check the box indicating whether or not the witness is testifying on behalf of a government entity, such as a Federal department or agency, or a State or local department, agency, or jurisdiction. Trade or professional associations of public officials are not considered to be governmental organizations.

Grants and Contracts (Item 5). Please list any Federal grants or contracts, or contracts or payments originating with a foreign government, that you or the entity(ies) you represent have received on or after January 1, 2013. For each Federal grant (or subgrant thereof) or contract (or subcontract thereof) related to the subject matter of the hearing, please include the amount and source of each. For each payment or contract originating with a foreign government related to the subject matter of the hearing, please include the amount and country of origin of each. Only grants, contracts, or payments related to the subject matter of the hearing must be listed.
3. ***Curriculum Vitae (Item 6).*** Please attach your CV to your completed disclosure form.
4. ***Submission.*** Please sign and date the form in the appropriate place. Please submit this form with your written testimony. Please note that under the Committee's rules, copies of a written statement of your proposed testimony must be submitted before the commencement of the hearing. To the greatest extent practicable, please also provide a copy in electronic format according to the Electronic Format Guidelines that accompany these instructions.

January 10, 2015

CURRICULUM VITAE


Nathan Fountain

Nathan B. Fountain, M.D.

Personal Data:

Work Address: University of Virginia School of Medicine
Department of Neurology, Box 800394
Charlottesville, VA 22908
Phone: 434-243-6281, Fax: 434-982-1726
E-mail: nbf2p@virginia.edu

Home Address: 3560 Meriwether Hill Lane
Charlottesville, Virginia 22901
Phone: 434-296-0417



Education:

1981-1985 Bachelor of Science in Zoology with Highest Distinction, May, 1985
University of Iowa, Iowa City, Iowa

1985-1989 Doctor of Medicine, May, 1989
University of Iowa College of Medicine, Iowa City, Iowa

Post-graduate Training and Fellowships:

1989-1990 Intern, Department of Internal Medicine
University of Virginia, Charlottesville, Virginia

1990-1993 Resident, Department of Neurology
University of Virginia, Charlottesville, Virginia

1992-1993 Chief Resident, Department of Neurology
University of Virginia, Charlottesville, Virginia

1993-1994 Clinical Neurophysiology/EEG and Epilepsy Fellowship
University of Virginia, Charlottesville, Virginia

1994-1996 Experimental/Clinical Epilepsy Fellowship
University of Virginia, Charlottesville, Virginia

Academic Appointments:

7/96-7/01	Assistant Professor, Department of Neurology University of Virginia School of Medicine, Charlottesville, Virginia
10/97-present	Director, F.E. Dreifuss Comprehensive Epilepsy Program University of Virginia School of Medicine, Charlottesville, Virginia
10/97- present	Director, EEG/Epilepsy Fellowship University of Virginia School of Medicine, Charlottesville, Virginia
2/98- present	Director, Rural Outreach Neurology Clinics University of Virginia Health Sciences Center, Charlottesville, Virginia
7/01-7/05	Associate Professor, Department of Neurology University of Virginia School of Medicine, Charlottesville, Virginia
7/05- 6/09	Associate Professor Without Term (tenure), Department of Neurology University of Virginia School of Medicine, Charlottesville, Virginia
7/09-present	Professor, Department of Neurology University of Virginia School of Medicine, Charlottesville, Virginia

Certification:

Federal Licensure Examination, 1989
American Board of Psychiatry and Neurology - *Neurology* (#41246) 1995-2005, 2005-2015
American Board of Psychiatry and Neurology - *Clinical Neurophysiology* (#1035), 1999-2009,
2010-2020
American Board of Psychiatry and Neurology - *Epilepsy* (#148), 2014-2024
American Board of Clinical Neurophysiology, 1997

Licensure:

Medical License for the Commonwealth of Virginia, 1992, exp 2/29/16 (#0101048670)
Medical License for the State of Tennessee, 1997, inactive (#29963)

Honors and Awards:

1985	Bachelor of Science with Special Honors
1982-1985	University of Iowa Honors Society Member
1982-1985	Iowa Foundation Scholarships
1984	Iowa Undergraduate Scholar
1985	University of Iowa Certificate of Achievement/Collegiate Scholar
1985	Medical Student Research Fellowship
1988	University of Iowa Class of 1934 Academic Scholarship

1989	Barry Freeman Fellowship for study in Papua New Guinea
1994	Epilepsy Foundation of America Clinical Research Grant
1995	Epilepsy Foundation of America Clinical Research Grant
1996	Alpha Omega Alpha Medical Honor Society
2007-present	Best Doctors in America
2007	Visiting Professorship, Ain Shams University, Cairo, Egypt
2010	Visiting Professorship, Anshan Changda Hospital, Anshan, China
2012	Keynote Speaker, Egyptian Society of Neurology Epilepsy Conference, Cairo

Professional Activities:

Editorial Boards

2000-2005	<i>Micromedex Diseasedex</i>
2002-2007	<i>American College of Physicians - Physicians Information and Education Resource (PIER)</i>
2005-2014	<i>Epilepsy Currents</i>
2014-present	Epilepsy.com

Journal Referee

1995-present	<i>Neurology</i>
1997-2000	<i>CNS Drugs</i>
1998-1999	<i>Drug Safety</i>
1999-2000	<i>Sleep Research Online</i>
2000-present	<i>Epilepsia</i>
2003-2004	<i>Clinical Neuropharmacology</i>
2003-present	<i>Epilepsy and Behavior</i>
2003-2004	<i>JAMA, Journal of the American Medical Association</i>
2007	<i>Neuropsychiatric Disease and Treatment</i>
2007	<i>Clinical Pharmacokinetics</i>
2007	<i>Drug Design, Development and Therapy</i>
2008-present	<i>Acta Neurologica Scandinavica</i>
2008-present	<i>Epilepsy Research</i>
2008-present	<i>Journal of Pediatric Neurology</i>
2008-present	<i>Mayo Clinic Proceedings</i>
2009-present	<i>European Journal of Neurology</i>
2009-present	<i>Clinical Neurophysiology</i>
2010-present	<i>Neurosurgery</i>
2011-present	<i>Annals of Neurology</i>
2012-present	<i>Seizure</i>
2013-present	<i>North African and Middle Eastern Epilepsy Journal</i>

Grant and Federal Review Committees

1998-1999	Scientific Review Committee, Comitato Telethon Grants, Rome, Italy
2000	Israel Science Foundation
2002	Georgian -U.S. Civilian Research and Development Foundation
2004	CDC Quality of Epilepsy Care Grant Review Panel, 2004-R19
2006	Epilepsy Quality of Care Measures, Expert Review Panel, Boston University

2007 CDC Epidemiology of Epilepsy Grant Review Panel, 2007-R05
 2009 CDC Epilepsy Special Emphasis Panel 2009
 2009-2010 FDA Advisory Committee Consultant, Peripheral and CNS Drugs
 2010-2014 FDA Advisory Committee Chair (11-14), Peripheral and CNS Drugs
 2014-2019 FDA Advisory Committee Consultant, Peripheral and CNS Drugs
 2010 EF Grant Review Panel, Targeted Initiative for Seniors
 2010-present EF Grant Reviews (Morbidity and Mortality in Epilepsy, Section Head)

Professional Societies: National Offices and Committees

American Academy of Neurology (AAN)

1999-2004 Epilepsy Education Committee
 2001-2002 Practice Parameter Reviewer Network
 2008-present Epilepsy Quality Performance Measures Work Group, Co-Chair
 2009 Scientific Abstract Review Committee
 2011 Neuropsychometric and Seizure Devices FDA Workshop Committee
 2011 Epilepsy Quality Metrics Analysis Group
 2014 Epilepsy Quality Measures Revision Work Group, Co-Chair
 2014 Scientific Abstract Review Committee

American Epilepsy Society (AES)

2001-2004 Annual Course Committee
 2002-2004 Scientific Program Committee
 2007-2010 Annual Course Committee
 2009-present Nonepileptic Seizures Task Force
 2010-present EMU Safety Committee
 2011-2013 Practice Management Committee, Quality Subcommittee chair

National Association of Epilepsy Centers (NAEC)

2005-present Board of Directors
 2006 Epilepsy Quality Care Indicators Committee
 2010-11 Treasurer
 2011-present Vice President

American Clinical Neurophysiology Society (ACNS)

2005-present Critical Care Monitoring Committee
 2008 Oral Board Examiner

Epilepsy Foundation (EF)

2007-present Professional Advisory Board (PAB), Chair-elect (2011-present)
 2008-2013 PAB Quality of Life Committee, chair (2011-2013)
 2010 PAB Epilepsy Referral Guidelines/Standards of Care Workgroup
 2010 EF/NICHQ Educational Stakeholder Conference, member
 2010-present Research Council

Epilepsy Research Foundation (ERF)

2011-2013 Board of Directors

American Board of Psychiatry and Neurology (ABPN)

2009-2013 Clinical Neurophysiology Certification Committee

American College of Emergency Physicians Policy Reviewer

2003 Clinical Policies Committee

Vision 20/20

2010-present NAEC Representative

2011-2012 Institute of Medicine (IOM) “Epilepsy Across the Spectrum” report
2013 Intractable Epilepsy Awareness Web-based IOM Tool Development

Professional Societies: Regional Offices and Committees

Epilepsy Foundation of Virginia
1999-2002 Professional Advisory Board
2002-2009 President
2009-present Professional Advisory Board Chair
Virginia Neurological Society
2003-2013 Executive Council; President (11-13), President Elect (09-11),
Vice-President (07-09), Treasurer (05-07), Councilor (03-05)

Professional Societies: Memberships

1992-present American Academy of Neurology (AAN)
1996-present American Epilepsy Society (AES)
1998-present American Clinical Neurophysiology Society (ACNS)
1998-present National Association of Epilepsy Centers (NAEC)

Advisory Boards, Speakers Bureaus, Grant Development Committees

1997-2002 Epilepsy Advisory Board, Athena Neurosciences
1997-2002 Speakers Bureau, Ortho-McNeil Pharmaceuticals
2000-2002 Speakers Bureau, UCB Pharma
2003-2006 Epilepsy Advisory Board, Med Pointe Pharmaceuticals
2004-2008 Epilepsy Drug Development Advisory Board, UCB Pharma
2004-2008 Epilepsy Drug Development Advisory Board, Schwarz Biosciences
2006-2008 NIH Monotherapy RCT Grant Development Committee (M. Privitera, PI)
2007 Schwarz SP902 Monotherapy Steering Committee
2008-2009 Prospective trial of levetiracetam for antiepileptogenesis after traumatic brain
injury grant development committee (P. Klein, multicenter PI)
2010-present US Status Epilepticus Treatment Trial Grant Development Committee

Institutional and Neurology Department Committees

2002-2003 Multiple Sclerosis Faculty Search Committee
2002-2003 Pediatric Epilepsy Faculty Search Committee
2003-2007 Health Services Foundation, Physician Advisory Council
2004-2007 Epilepsy Faculty Search Committee
2005-2007 Research Administration and Compliance Computing Initiative
2008-2011 Dean’s Research Advisory Committee, Chair 2010
2008 Investigator Advisory Committee of Institutional Review Boards
2010 Epic EMR Research Committee
2010 Epilepsy Neurology Faculty Search Committee
2010 Pediatric Neurology Faculty Search Committee
2010 Clinical Research Advisory Committee

School of Medicine Standing Teaching Assignments

1994- present Neurology Physical Diagnosis Section (POM), Course Director
1996-2001 Clinical Neurophysiology Resident Lecture Series, Lecturer

1996- present Neurology Clerkship; Problem Set Discussion Preceptor, Lecturer
 1997- present Epilepsy Fellows Weekly Reading Conference; Preceptor, Lecturer
 1997-1998 Medical Neuroscience Course; Lecturer, Anatomy Lab Instructor, Case Discussion Preceptor
 1998-1999 Graduate Dissertation Committee, Greg Harrington, Physics and Engineering Departments, "Fourier generated empirical functional MRI models"
 1999- present Medical Scientist Training Program Practice of Medicine, Course Preceptor
 1999- present Epilepsy Nurse Conference
 2002-2003 Graduate Dissertation Committee, Teiko Miyashita, Department of Psychology, "Modulation of hippocampal noradrenergic systems as a neural substrate for memory enhancement initiated by peripheral arousal"

Fellowship Trainees:

Epilepsy/EEG Fellowship Trainees

Mustapha Danesi, MBBS	1996-1998	Christopher Wright, MD	2005-2007
Robert Armstrong, MD	1997-1998	Ilona Humes, MD	2005-2007
Jonathan Artz, MD	1997-1998	Andrew Stefanick, MD	2006-2007
James Kiely, MD, PhD	1998-2000	Rhunelle Murray, MD	2007-2009
Naser Elbalalesy, MD	1999-2000	Gabriel Martz, MD	2007-2009
Michael Frucht, MD	1999-2001	Russell Bailey, MD	2008-2010
Avinash Prasad, MD	1999-2001	Jennifer Langer, MD	2009-2011
Anthony May, MD	2000-2002	Utku Uysal, MD	2009-2011
Bassel Shneker, MD	2000-2002	Matthew Wong, MD	2010-2012
Wendy Waldman, MD	2001-2002	John Mytinger, MD	2010-2012
Stacey Epps, MD	2001-2002	Heba Afeefy, MD	2011-2013
Firas Beitinjaneh, MD	2002-2003	Nicole Sodeifi, MD	2012-2013
William Taft, MD, PhD	2002-2003	Bander Alsowaity, MD	2012-2013
Jesus Felix Martinez, MD	2002-2005	Holly Hensley-Judge, MD	2012-2013
Annamarei Ranta, MD	2003-2004	Chad Saunders, MD	2013-2014
Sanjiv Sahoo, MD	2003-2004	Scott Kohler, MD	2013-
Paul Lyons, MD, PhD	2004-2006	Philip Tseng, MD	2013-

International Visiting Fellows:

Hugo Mora, MD	2/04-5/04	From University of El Salvador, El Salvador
Clara Dawodu, MD	1/05-3/05	From Lagos State University, Nigeria (UVA Center for Global Health Award)
Kristin Guilliams, MD	1/06-3/06	To San Salvador, El Salvador, with Dr. JF Martinez (UVA Center for Global Health Award)
Ping Xu, MD	6/09-8/09	From Anshan University Hospital, China (General neurology)
Yulin Song, MD	6/09-8/09	From Anshan University Hospital, China (General neurology)

Grants and Contracts:

Investigator Initiated Research Grants:

- 1994-1995 Dormancy of inhibitory interneurons in an animal model of epilepsy. Epilepsy Foundation Clinical Research Grant, PI (Eric Lothman, M.D., Ph.D, mentor)
- 1995-1996 Focal entorhinal cortex lesions cause distant hyperexcitability in the hippocampal CA1 region. Epilepsy Foundation Clinical Research Grant, PI (Eric Lothman, MD, PhD and Edward Bertram MD, mentors)
- 1998-2001 Inhibition in entorhinal cortex in epilepsy. NINDS K08 NS01992, PI.
- 2004-2006 Early Randomized Surgical Epilepsy Trial (ERSET). NINDS U01 NS042372, site PI (J. Engel, multicenter PI)
- 2007-2009 Progesterone therapy for women with Epilepsy. NIH RO1 NS39466, site PI (A. Herzog, multicenter PI)
- 2009-2014 Radiosurgery versus open surgery epilepsy trial (ROSE), R01 NS 058634-01A2, site PI (N. Barbaro, M. Quigg multicenter co-PIs)
- 2010-2014 Epilepsy Phenome/Genome Project (EPGP), NINDS U01 NS 053998, site PI (D. Lowenstein, multicenter PI)
- 2011-2013 2-Deoxyglucose: Proof of Principal Clinical Trial, Epilepsy Research Foundation, PI (on hold)
- 2015-2017 Focused Ultrasound for Subcortical Epilepsy (FUSE) study, PI, Epilepsy Foundation

Clinical Drug and Device Epilepsy Trials, UVA Principal Investigator (*Multicenter PI):

- 1997 Double-blind study of the safety, tolerability, and antiepileptic activity of ganaxolone in patients with complex partial seizures. CoCensys
- 1998 Multi-center, open-label, exploratory study of ucb LO59 in children (6-12 year old) with partial onset seizures (N151). UCB Pharma
- 1998-2005 Long-term, follow-up study of ucb LO59 in children (N157). UCB Pharma
- 1998-1999 Pregabalin BID randomized, double-blind study (1008-034). Parke-Davis
- 1998-2005 Open-label, follow-on study of pregabalin to 1008-034 (1008-035). Pfizer
- 1999-2000 Prevalence of metabolic and menstrual irregularities in women with epilepsy on lamotrigine or valproate monotherapy (30006). Glaxo Wellcome
- 1999 Double-blind RCT of gabapentin for intractable seizures in children 1 to 36 months old (305). Parke-Davis
- 1999-2000 *Phase II study of harkoseride for partial seizures (01-201). Harris FRC
- 1999-2001 Open-label extension harkoseride study to 01-201 (01-202). Harris FRC
- 1999-2002 Safety/efficacy of two monotherapy doses of topiramate for newly diagnosed or recurrent epilepsy (106). R.W. Johnson.
- 1999-2001 Double-blind randomized trial of levetiracetam for intractable partial seizures in children (N159). UCB Pharma
- 2000-2002 RCT evaluating development of polycystic ovarian syndrome in newly diagnosed epilepsy initiating lamotrigine vs. valproate (300007). Glaxo Wellcome.
- 2000-2001 Zonisamide 25 mg dose titration study (501). Elan

2000-2003 Double-blind study of Lamictal for seizures in patients 1-24 mos. old (20006) and extension study (20007). Glaxo Wellcome

2001-2003 *Pharmacokinetics of levetiracetam in 4-14 year old children with partial seizures and concomitant carbamazepine, valproate or gabapentin (N01010). UCB

2001-2002 Open-label, dose titration tolerability and efficacy trial of SPM927 as adjunctive therapy of partial seizures (SP607). Schwarz BioSciences

2001-2010 Open-label extension tolerability and efficacy trial of long-term oral SPM927 as adjunctive therapy for partial seizures (SP615). Schwarz BioSciences

2002-2003 Double-blind, randomized dose escalation (200, 400, 600 mg/day) trial of SPM927 for refractory partial-onset seizures (SP667). Schwarz BioSciences

2002-2004 Phase II double-blind efficacy and safety study of talampanel adjunctive therapy for partial seizures (IXL-201-14-189). IVAX Laboratories

2002-2008 Talampanel open-label follow-on study to IXL-201 (IXL-201F-14-189). IVAX.
2004 Randomized, double-blind, double-dummy pharmacokinetic study of intravenous SPM927 as replacement of oral drug (SP616). Schwarz BioSciences

2004-2005 Double-blind, placebo controlled dose-ranging study of RWJ-333369 for adjunctive therapy of refractory partial seizures (EPY-2003). RW Johnson

2004-2005 Double-blind, randomized Phase III trial of SPM927 for refractory partial-onset seizures (SP754). Schwarz BioSciences

2004-2009 Open-label long-term study of SPM927 (SP756). Schwarz BioSciences

2005-2006 Exploratory study of seletracetam for partial seizures (N01191). UCB Pharma

2005-2006 *Exploratory study of seletracetam for refractory partial seizures with concomitant levetiracetam (N01192). UCB Pharma

2005-2006 Phase 3 dose-escalation study of E2007 for refractory partial seizures(206). Eisai

2005-present Stimulation of Anterior Nucleus of Thalamus for Epilepsy (SANTE). Medtronics

2006 Unilateral interaction study of brivaracetam on phenytoin (N01172). UCB

2006 *Brivaracetam for Unverricht-Lundborg disease (N01236). UCB

2006-2009 Open-label long-term safety/efficacy of brivaracetam for epilepsy (N01125).UCB

2006-2007 Retigabine RCT (RESTORE) for refractory partial seizures (301). Valeant

2006-2010 Randomized controlled trial of a responsive neurostimulation device for control of refractory partial seizures. Neuropace

2007 *Carisbamate 400 mg unilateral interaction study with phenytoin (N01010). RW Johnson

2008 Brivaracetam for refractory partial seizures phase 3 study (N01253). UCB

2008-2010 *Lacosamide tolerability study of 15 min IV 15 load (SP925). UCB

2008-2013 Lacosamide monotherapy study RCT and open label (SP902 and 904). UCB.

2009-2010 *Carisbamate 800&1200mg phenytoin interaction study (1037). RW Johnson

2010-2012 Phase III eslicarbazepine (BIA-209) 800 vs 1200 mg for partial seizures (S304)

2010-present Phase III responsive neurostimulation long-term treatment. Neuropace

2010 Phase II compound VX08-765 vs. placebo (study 401). Vertex

2011-2012 Tolerability of brivaracetam IV infusion and bolus (N01258). UCB

2011-2012 Tolerability of IV Carbamazepine (13181A). Lundbeck

2011-on hold [Tolerability and safety of intranasal midazolam. Upshire-Smith]

2011-2014 Phase 3 RCT brivaracetam for partial seizures (N01358). UCB

2011-present Open-label long term study of brivaracetam (N01379). UCB

2012-2013 Phase II RCT of YKP3089 for partial seizures (C013). SK Life Sciences
 2012 [Phase IIb VX08-765 vs. placebo for partial epilepsy (study 402). Vertex]
 2013 [Inpatient open-label epilepsy study of IPX218 (IPX218 B12-02). Impax]
 2013- present Dose ranging RCT of YKP3089 for partial seizures (C017). SK Life Sciences
 2014-present PK study of nasal vs rectal diazepam (EP1019)
 2014-present Chronic intermittent use of diazepam nasal spray for cluster seizures (EP1025)

Clinical Drug Studies (Sub-Investigator):

1993-1996 Efficacy of zonisamide monotherapy (810-921), Dainippon Pharm.
 1993-1996 Baseline controlled zonisamide partial seizure study (810-920). Dainippon Pharm.
 1995-1998 Open-label intermittent rectal diazepam for acute repetitive seizures (004). Athena.
 1995-2000 Clinical use of vigabatrin for partial seizures (098). Marion Merrell Dow.
 1995-2001 Long-term safety and efficacy of zonisamide; 810-921 extension. Dainippon Pharm.
 1995-1997 Extension study of vigabatrin in children (201). Marion Merrell Dow.
 1995-1997 Vigabatrin vs. placebo in children: dose response study (118). Marion Merrell Dow.
 1996-1999 Open-label Lamictal pediatric extension study (41). Glaxo-Wellcome.
 1996-2000 Open-label study of vigabatrin monotherapy for CPS (242). Marion Merrell Dow.

Public Health Care Grants:

1997-2003 Virginia Department of Health - Children Specialty Services. Administration of Neurology Southwest Virginia rural field clinics (\$110,000/year)
 2003-present Virginia Department of Health - Care Connection for Children. Administration of Neurology Southwest Virginia rural field clinics (\$68,000/year)

Peer Reviewed Publications (trainees underlined):

1. **Fountain, N.B.**, Lothman, E.W. Pathophysiology of status epilepticus. Journal of Clinical Neurophysiology 1995;12(4):326-342.
2. **Fountain, N.B.**, Eberhard, D.A. Primary angiitis of the CNS associated with cerebral amyloid angiopathy: report of two cases and review of the literature. Neurology 1996;46;190-197.
3. Bear, J., **Fountain, N.B.**, Lothman, E.W. Responses of the superficial entorhinal cortex *in vitro* in slices from naive and chronically epileptic rats. Journal of Neurophysiology 1996;76(5):2928-2940.
4. **Fountain, N.B.**, Kim, J.S., Lee, S.I. Sleep deprivation activates epileptiform discharges independent of the activating effects of sleep. Journal of Clinical Neurophysiology 1998;15(1):69-75.
5. Fountain, N.B., Bear, J., Bertram, E.H., Lothman, E.W. Responses of deep entorhinal cortex are epileptiform in an electrogenic rat model of chronic temporal lobe epilepsy. Journal of Neurophysiology 1998;80:230-240.

6. Bertram, E.H., Zhang D.X., Mangan P., **Fountain, N.**, Rempe D. Functional anatomy of limbic epilepsy - a proposal for central synchronization of a diffusely hyperexcitable network. *Epilepsy Research* 1998;32:194-205.
7. **Fountain, N.B.**, Lopes, M.B.S. Control of primary angiitis of the CNS associated with cerebral amyloid angiopathy by cyclophosphamide alone. *Neurology* 1999;52(3):660-662.
8. Quigg, M., **Fountain, N.B.** Conduction aphasia elicited by stimulation of the left posterior superior temporal gyrus. *Journal of Neurosurgery, Neurology & Psychiatry* 1999;66:393-396.
9. **Fountain, N.B.**, Adams, R. E. Midazolam treatment of acute and refractory status epilepticus. *Clinical Neuropharmacology* 1999;22(5):261-267.
10. **Fountain, N.B.** Status epilepticus: risk factors and complications. *Epilepsia* 2000;41(Suppl 2):S23-S30.
11. Laxer K, and Ganaxolone Presurgical Study Group. Assessment of ganaxolone anticonvulsant activity using a randomized double-blind, presurgical trial design. *Epilepsia* 2000;41(9):1187-1194.
12. Frucht M.M., Quigg, M., Schwaner, C., **Fountain, N.B.** Distribution of seizure precipitants among epilepsy syndromes. *Epilepsia* 2000;41:1534-1539.
13. **Fountain, N.B.**, Waldman, W.A. Effects of benzodiazepines on triphasic waves: Implications for nonconvulsive status epilepticus. *Journal of Clinical Neurophysiology*, 2001;18(4):345-352.
14. Pellock JM, Glauser TA, Bebin EM, **Fountain NB**, Ritter FJ, Coupez RM, Shields WD. Pharmacokinetic Study of Levetiracetam in Children. *Epilepsia* 2001;42(12):1574-1579.
15. Glauser TA, Pellock JM, Bebin EM, **Fountain NB**, Ritter FJ, Jensen CM, Shields WD. Efficacy and safety of levetiracetam in children with partial seizures: an open-label trial. *Epilepsia* 2002;43:518-524.
16. Quigg MS, Armstrong RF, Farace E, **Fountain NB**. Quality of life outcome is associated with cessation rather than reduction of psychogenic nonepileptic seizures. *Epilepsy and Behavior* 2002;3:455-459.
17. Gullapalli D, **Fountain NB**. Clinical correlation of occipital intermittent rhythmic delta activity (OIRDA). *Journal of Clinical Neurophysiology*, 2003;20(1):35-41.
18. Shneker BE, **Fountain NB**. Assessment of acute morbidity and mortality in nonconvulsive status epilepticus. *Neurology* 2003;61:1066-1073.
19. **Fountain, N.B.**, May A.C. Epilepsy and Athletics. *Clinics in Sports Medicine* 2003;33(3):605-616.

20. Kirby D, **Fountain NB**, Quigg MS. Standardized mental status testing for nonconvulsive status epilepticus. *American Journal of Electroneurodiagnostic Technology* 2004;44(3):199-201.
21. Sahoo SK, **Fountain NB**. Epilepsy in football players and other land-based contact/collision sport athletes: when can they participate and is there an increased risk? *Current Sports Medicine Reports*, 2004;3(5):284-5.
22. Glauser TA, Ayala R, Elterman RD, Mitchell WG, Van Orman CB, Gauer LJ, Lu Z for the N159 Study Group. Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. *Neurology*. 2006;66(11):1654-60.
23. **Fountain NB**, Conry JA, Rodríguez-Leyva I, Gutierrez-Moctezuma J, Salas E, Coupez R, Stockis A, Lu Z. Prospective Assessment of Levetiracetam Pharmacokinetics During Dose Escalation in 4- to 12-Year-Old Children With Partial-Onset Seizures on Concomitant Carbamazepine or Valproate. *Epilepsy Research* 2007;74:60-69.
24. Pugh MJ, Berlowitz DR, Montouris G, Bokhour B, Cramer JA, Bohm V, Bollinger M, Helmers S, Ettinger A, Meador KJ, **Fountain N**, Boggs J, Tatum WO 4th, Knoefel J, Harden C, Mattson RH, Kazis L. What constitutes high quality of care for adults with epilepsy? *Neurology* 2007;69:2020-2027.
25. Biton V, Rosenfeld WE, Whitesides J, **Fountain NB**, Vaiciene N, Rudd GD. Intravenous lacosamide as replacement for oral lacosamide in patients with partial-onset seizures (SP616). *Epilepsia* 2008;49(3):418–424.
26. Fisher R for the SANTE Study Group. Electrical Stimulation of the Anterior Nucleus of Thalamus for Treatment of Refractory Epilepsy. *Epilepsia* 2010;51(5):899–908.
27. Labiner DM, Bagic AI, Herman ST, **Fountain NB**, Walczak TS, Gumnit RJ; for the National Association of Epilepsy Centers. Essential services, personnel, and facilities in specialized epilepsy centers-Revised 2010 guidelines. *Epilepsia* 2010;51:2322-2333.
28. Chung S, Ben-Menachem E, Sperling M, Rosenfeld W, **Fountain NB**, Benbadis S, Hebert D, Isojarvi J, Doty P. Examining the Clinical Utility of Lacosamide: Pooled Analyses of Three Phase II/III Clinical Trials. *CNS Drugs* 2010;24(12):1041-1054.
29. **Fountain NB**, Van Ness PC, Swain-Eng R, Tonn S, Bever CT Jr; For the American Academy of Neurology Epilepsy Measure Development Panel and the American Medical Association–Convened Physician Consortium for Performance Improvement Independent Measure Development Process. Quality improvement in neurology: AAN epilepsy quality measures: Report of the Quality Measurement and Reporting Subcommittee of the American Academy of Neurology. *Neurology* 2011;76(1):94-99.
30. Morrell MJ and RNS System in Epilepsy Study Group. Responsive cortical stimulation for the treatment of medically intractable partial epilepsy. *Neurology* 2011;77(13):1295-304.

31. Herzog AG et al for Progesterone Trial Study Group. Variation of seizure frequency with ovulatory status of menstrual cycles. *Epilepsia* 2011;52(10):1843-8.
32. Cock HR for the ESETT Group. Established status epilepticus treatment trial (ESETT). *Epilepsia*. 2012;52 Suppl 8:50-2.
33. Langer JE, Lopes B, **Fountain NB**, Pranzatelli MR, Thiele EA, Rust RS, Goodkin HP. An unusual presentation of anti-Hu associated paraneoplastic limbic encephalitis. *Dev Med Child Neuro* 2012;Feb.
34. Engel J Jr, et al. Early randomized surgery for epilepsy trial (ERSET). *JAMA* 2012;307(9):922-930.
35. Wicks P, **Fountain NB**. Patient Assessment of Physician's Performance of Epilepsy Quality Care Measures. *Neurology Clinical Practice* 2012;2;335-342.
36. **Fountain NB**, Krauss G, Isojarvi J, Dilley D, Doty P, Rudd GD. Safety and tolerability of adjunctive lacosamide IV loading dose for in lacosamide-naïve patients with partial-onset seizures. *Epilepsia* 2013;54(1):58-65.
37. Halford JJ, Schalkoff RJ, Zhou J, Benbadis SR, Tatum WO, Turner RP, Sinha SR, **Fountain NB**, Arain A, Pritchard PB, Kutluay E, Martz G, Edwards JC, Waters C, Dean BC. Standardized Database Development for EEG Epileptiform Transient Detection: EEGnet Scoring System and Machine Learning Analysis. *Journal Neuroscience Methods* 2013;212;308–316.
38. Hirsch LJ, Laroche SM, Gaspard N, Gerard E, Svoronos A, Herman ST, Mani R, Arif H, Jette N, Minazad Y, Kerrigan JF, Vespa P, Hantus S, Claassen J, Young GB, So E, Kaplan PW, Nuwer MR, **Fountain NB**, Drislane FW. American Clinical Neurophysiology Society's Standardized Critical Care EEG Terminology: 2012 version. *J Clin Neurophysiol* 2013;30:1-27
39. Winawer MR, Connors R; EPGP Investigators. Evidence for a shared genetic susceptibility to migraine and epilepsy. *Epilepsia* 2013 Feb;54:288-95.
40. Epi4K Consortium & Epilepsy Phenome/Genome Project. De novo mutations in epileptic encephalopathies. *Nature* 2013;501:217-221.
41. EPGP Collaborative. The epilepsy phenome/genome project. *Clin Trials* 2013 Aug;10(4):568-86.
42. Bleck T, Cock H, Chamberlain J, Cloyd J, Connor J, Elm J, **Fountain N**, Jones E, Lowenstein D, Shinnar S, Silbergleit R, Treiman D, Trinka E, Kapur J. The established status epilepticus trial 2013. *Epilepsia* 2013;54 Suppl 6:89-92.
43. Friedman D, Fahlstrom R; EPGP Investigators. Racial and ethnic differences in epilepsy classification among probands in the Epilepsy Phenome/Genome Project (EPGP). *Epilepsy Res*. 2013;107(3):306-10.

44. Epi4K Consortium. De novo mutations in synaptic transmission genes including DNMI1 cause epileptic encephalopathies. *Nature* 2013;501(7466):217-21.
45. Widdess-Walsh P, Dlugos D, Fahlstrom R, Joshi S, Shellhaas R, Boro A, Sullivan J, Geller E; EPGP Investigators. Lennox-Gastaut syndrome of unknown cause: phenotypic characteristics of patients in the Epilepsy Phenome/Genome Project. *Epilepsia* 2013;54(11):1898-904.
46. Greyson B, **Fountain NB**, Derr LL, Broshek DK. Out-of-Body Experiences Associated with Seizures. *Frontiers in Human Neuroscience* 2014 Feb 13;8:65.
47. Greyson B, **Fountain NB**, Derr LL, Broshek DK. Mystical Experiences Associated With Seizures. *Religion, Brain & Behavior* 2014, accepted.
48. Heck CN, et al. Two-year seizure reduction in adults with medically intractable partial onset epilepsy treated with responsive neurostimulation: Final results of the RNS System Pivotal trial. *Epilepsia* 2014;55(3):432-41.
49. Langer J, **Fountain NB**. An Observational Study of Current Treatment for Generalized Convulsive Status Epilepticus. *Epilepsy and Behavior* 2014;37:95-99.
50. Rosenfeld W, **Fountain NB**, Kaubrys G, Ben-Menachem E, McShea C, Isojarvi J, Doty P; the SP615 Study Investigators. Safety and efficacy of adjunctive lacosamide among patients with partial-onset seizures in a long-term open-label extension trial of up to 8 years. *Epilepsy & Behavior* 2014;41:164–170.
51. EuroEPINOMICS-RES Consortium; Epilepsy Phenome/Genome Project; Epi4K Consortium. De Novo Mutations in Synaptic Transmission Genes Including DNMI1 Cause Epileptic Encephalopathies. *Am J Hum Genet* 2014 Oct 2;95(4):360-70.
52. Morrell M, et al. Long-term treatment with responsive brain stimulation in adults with medically intractable partial onset seizures, 2015, submitted.
53. Salinova et al. Long-term efficacy and safety of thalamic stimulation for drug resistance partial epilepsy. *Neurology* 2015; accepted.
54. Bergey GC, Morrell M, Mizrahi EM, Goldman AM, King-Stephens D. Long-term treatment with responsive brain stimulation in adults with refractory partial seizures. *Neurology* 2015;accepted.
55. Mefford, EPGP Study Group. CNV analysis from exome data in 349 patients with epileptic encephalopathy. *Ann Neurology* 2015; accepted.
56. King-Stephens D, et al. Lateralization of Mesial Temporal Lobe Epilepsy with Long-term Ambulatory Electrocoricography. 2015; submitted.
57. **Fountain N**, Van Ness PC, Bennett A, Absher J, Patel AD, Sheth KN, Gloss DS, Morita DA, Stecker S. Quality improvement in neurology: Epilepsy Update Quality Measurement Set.

Neurology 2015; accepted.

Books, Chapters, Editorials, Other:

1. Jew, J.Y., **Fountain, N.**, Jew, E.Y. Morphological detection of neuropeptides: comparison of methods. In: Conn P.M. Methods in Neuroscience, Vol. 6: Neuropeptide Technology. pp. 130-147, 1991.
2. **Fountain, N.B.** In-Memoriam: Eric Lothman. *Journal of Clinical Neurophysiology* 1995;12(4):400.
3. **Fountain, N.B.**, Eberhard, D. Amyloid Angiopathy (Correspondence). *Neurology* 1997;48(1):291.
4. Miller, J.Q., **Fountain, N.B.**, Editors, Neurology Recall. Baltimore: Williams and Wilkins, 1997.
5. **Fountain, N.B.** Neurology, In: Bergin J. Medical Recall. Baltimore: Williams and Wilkins, 1997.
6. **Fountain, N.B.**, Bleck T.P. Mechanism of action of drugs for status epilepticus. *Epilepsy Quarterly* 1996;4(2):5-8.
7. Dreifuss FE, **Fountain NB**. Classification of epileptic seizures and the epilepsies with drugs of choice. In: Eadie, M.J. and Vajda, F. *Handbook of Experimental Pharmacology, Vol 133: Antiepileptic Drug Pharmacology and Therapeutics*. Germany: Springer-Verlag, 1999, p 1-17.
8. **Fountain, N.B.**, Dreifuss, F.E. The future of valproate. In: Löscher, W. Milestones in Drug Therapy, Valproate. Germany: Birkhäuser, 1999, pp. 265-276.
9. **Fountain, N.B.**, Dreifuss, F.E. Seizure Disorders. In: Koller, W.C. Current Practice of Medicine, vol. 2, no. 5. Philadelphia: Current Medicine Inc, 1999, pp. 723-731.
10. **Fountain, N.B.**, Levy, R., Lublin, F., Solomon, S. Common Conditions 6: Migraine, Epilepsy, MS. *Patient Care* 1999;33:150-168.
11. **Fountain, N.B.** Case studies: Convulsive seizure. In: MyPatient.com. On-line publication, [<http://www.MyPatient.com>]. 2000.
12. **Fountain, N.B.** Seizures (Epilepsy). In: Koller, W.C. Best Practice of Medicine. New York: Micromedex. 2001.
13. **Fountain, N.B.** Seizures. In, Gotto A (ed.): DISEASEDEX(M) - General Medicine, June 18, 2004. MICROMEDEX, Greenwood Village, CO, [www.mdx.com/products/diseasedexgeneral]
14. **Fountain, N.B.** Seizures and Epilepsy in Adolescents and Adults. In: Rakel and Bope. Conn's Current Therapy, 2002. Philadelphia: WB Saunders, 2002, pp884-893.

15. **Fountain, N.B.** Seizures and Epilepsy. In: Goldmann, DR. Physicians= Information and Education Resource (PIER) . American College of Physicians-American Society of Internal Medicine. On-line publication, [<http://PIER.ACPOne.org>]. 2002. Update July 22, 2003.
16. **Fountain, N.B.** Book Review, Treatment of Epilepsy: Principles and Practice, 3rd ed. Elaine Wyllie. Neurology 2002;58:1578-1579.
17. **Fountain, N.B.** Review: Origin 7.0 Graphing Software, American Journal of Electroneurodiagnostic Technology 2002;42(3):172-172.
18. Swerdlow, R., **Fountain, N.B.**, Nathan, B. Neurology, In: Bergin J. Medical Recall, 2nd Edition. Philadelphia: Lippincott Williams and Wilkins, 2003.
19. Miller, J.Q., **Fountain, N.B.**, Editors, Neurology Recall, 2nd Edition. Philadelphia: Lippincott Williams and Wilkins, 2003.
20. Shneker B., **Fountain, N.B.** Epilepsy. Disease-A-Month 2003;49(7):426-78.
21. **Fountain, N.B.** Review: S-PLUS Statistics and Graphing Software. American Journal of Electroneurodiagnostic Technology 2003;43:265-266.
22. Ranta, A., **Fountain, N.B.** Seizures and Epilepsy in Adolescents and Adults. In: Rakel and Bope. Conn's Current Therapy, 2005. Philadelphia: Elsevier Saunders, pp 1021-1031.
23. Bassin SL, **Fountain NB**, Bleck TP. Seizures in the intensive care unit. In: Hall, Schmidt and Wood. Principles of Critical Care 3rd Edition. McGraw-Hill, 2005, pp997-1006.
24. **Fountain, N.B.** Cellular damage and the neuropathology of status epilepticus. In: FW Drislane. Status Epilepticus: A Clinical Perspective. New Jersey: Humana Press, 2005, pp181-193.
25. **Fountain NB.** Epilepsy (Seizures). In: NJ Salkind. Encyclopedia of Human Development. Sage Publishing, 2005.
26. Ranta, A., **Fountain, N.B.** Seizures and Epilepsy in Adolescents and Adults. In: Rakel and Bope. Conn's Current Therapy, 2006. Philadelphia: Elsevier, 2006, pp 1095-1105.
27. **Fountain NB**, Freeman JM. EEG is an essential clinical tool: Pro and con. *Epilepsia* 2006;47(Suppl. 1):23-25.
28. Kubersky L, Swerdlow, R., **Fountain, N.B.**, Nathan, B. Neurology, In: Bergin J. Medical Recall, 3rd Edition. Philadelphia: Lippincott Williams and Wilkins, 2007.
29. **Fountain NB.** Transcranial Magnetic Stimulation and Sleep Deprivation as Experimental Tools: the Excitement of Sleep Deprivation. *Epilepsy Currents* 2007;7:151-152.
30. **Fountain NB.** Is it time for routine EEG monitoring after intracerebral hemorrhage? *Neurology* 2007;69:1312-1313.

31. **Fountain NB.** Evidence for Functional Impairment But Not Structural Disease in Benign Rolandic Epilepsy. *Epilepsy Currents* 2008;8:14-16.
32. **Fountain NB.** A frontal assault on the generalized nature of JME. *Epilepsy Currents* 2008;8(6):152–153.
33. **Fountain NB.** Prognosis and Outcomes in Nonconvulsive Status Epilepticus. In: F Drislane and P Kaplan, Nonconvulsive Status Epilepticus. New York, NY: Demos, 2009, pp273-280.
34. Kubersky L, Swerdlow, R., **Fountain, N.B.**, Nathan, B. Neurology, In: Bergin J, Advanced Medicine Recall. Philadelphia: Lippincott Williams and Wilkins, 2009.
35. **Fountain NB.** A pregnant pause to consider the teratogenicity of topiramate. *Epilepsy Currents* 2009;9(2):36-38.
36. **Fountain NB.** Should Levetiracetam Replace Phenytoin for Seizure Prophylaxis After Neurosurgery? *Epilepsy Currents* 2009;9(3):71-2.
37. Kubersky L, Swerdlow, R., **Fountain, N.B.**, Nathan, B. Neurology, In: Bergin J, Advanced Medical Recall, 1st Edition. Philadelphia: Lippincott Williams and Wilkins, 2009.
38. **Fountain NB**, Cole AJ. Pharmacologic treatment of epilepsy. *CNS Spectr.* 2010 Mar;15(3 Suppl 5):4-6.
39. **Fountain NB.** Choosing Among Antiepileptic Drugs. *American Academy of Neurology Continuum* 2010;Jun 16(3):121-135.
40. Southerland A, **Fountain NB**, Nathan B. Neurology, In: Bergin J, Medicine Recall, 4th Edition. Philadelphia: Lippincott Williams and Wilkins, 2010, submitted.
41. **Fountain NB.** Manual of Antiepileptic Drug Therapy. West Islip, NY: Professional Publications Inc., 2010.
42. Wong MH, **Fountain NB.** Lacosamide for the treatment of partial-onset seizures, *Therapy* 2010, in press.
43. **Fountain NB.** Complex partial status epilepticus. In: Stern J and Servin J (Eds), Atlas of Video EEG Monitoring, New York: McGraw-Hill, 2010.
44. Huff JS, **Fountain NB.** Pathophysiology and definitions of seizures and status epilepticus. *Emergency Medicine Clinics of North America* 2011;29(1):1-13.
45. Uysal U, **Fountain NB.** Seizures and Epilepsy in Adolescents and Adults. In: Rakel and Bope. Conn's Current Therapy, 2011. Philadelphia: Elsevier, submitted.
46. Shneker BF, **Fountain NB.** Anti-Epileptic Drug Selection for Partial Onset Seizures. *Current Treatment Options in Neurology* 2012;14:356–368.

47. Wong MH, Fountain NB. Generalized Periodic Discharges. In: LaRoche S (ed), Handbook of ICU EEG Monitoring. New York: Demos, 2012.
48. **Fountain NB**. Obliterating the Seizure Focus in AVMs is Effective: More Clinical Data Confirming Common Sense. *Epilepsy Currents* 2013;13(1):9-10.
49. Gumnit RJ, Labiner DM, **Fountain NB**, Herman ST. Data on Specialized Epilepsy Centers. In: England MJ, Liverman CT, Schultz AM, Strawbridge LM (eds), Epilepsy Across the Spectrum, Institute of Medicine Committee on the Public Health Dimensions of the Epilepsies. Washington DC: The National Academic Press, 2012.
50. **Fountain NB**. Delivering Quality Epilepsy Care. *Curr Opinion Neuro* 2013;26:174-178.
51. **Fountain NB**, Fugate, JE. Refractory Status Epilepticus: What to put down -the anesthetics or the patient? *Neurology* 2014;82:650-651.
52. Bailey RC, **Fountain NB**. Update on the potential use of lacosamide in the treatment of partial-onset seizures. *Frontiers Neurology* 2015 accepted.
53. Grunsfeld AA, Sandip, Servin J, **Fountain NB**. Status Epilepticus. In: Ramano E (Ed), *Il Malato Critico (The Critically Ill Patient)*. Utet Publishing, Milan. In preparation.
54. **Fountain NB**. Monitoring of Antiepileptic Drug Therapy. In: UpToDate, Rose, BD (Ed), UpToDate, Waltham, MA, submitted.

Abstracts:

1. Jew, J., Fountain, N. Evaluation of procedures for ultrastructural immunohistochemistry. *Anat Record* 211(3):92a, 1985.
2. Williams, T.H., Jew, J., Fountain, N. Angiotensin II-like peptide in rat brain; with which subcellular component is it associated? *Anat Record* 211(3):215A, 1985.
3. Fountain, N.B., Kim J.S., Lee, S.I. Sleep deprivation activates epileptiform discharges independent of the effects of sleep. *J Clin Neurophysiol* 1995;12:511.
4. Fountain, N.B., Bertram, E.H., Jackson, T., Goble, J., Laws, E. 3-D reconstruction of MRI allows correlation of neocortical electroencephalographic seizure onset with cortical abnormalities. *Epilepsia* 1995;36(Suppl. 4):170.
5. Fountain, N.B., Bear J., Lothman, E.W., Bertram, E.H. Intracellular entorhinal cortex responses are epileptiform in a model of chronic epilepsy. *Epilepsia* 1996;37(Suppl.5):65.
6. Fountain, N.B., Quigg M.S., Bertram, E.H., Jackson, T., Laws, E. Characteristics and anatomic location of language abnormalities induced by cortical stimulation. *Epilepsia* 1997;38(Suppl. 8):6.
7. Armstrong, R.A., Farace, E., Fountain, N.B., Quigg M.S. Seizure frequency does not predict quality of life following diagnosis of psychogenic non-epileptic seizures. *Epilepsia* 1998;39(Suppl. 6):217.
8. Fountain, N.B., Segar, F.E., Laws, E.R., Bertram, E.H. Entorhinal-hippocampal evoked responses using macro- and micro-electrodes in human epilepsy. *Epilepsia* 1998;39(Suppl. 6):202.

9. Messenheimer JA, Haynie CJ, Risner ME and the Lamictal US 41 Pediatric Study Group. Long-term tolerability of Lamictal in Pediatric Patients. *Epilepsia* 1998;39(Suppl. 6):51.
10. Pellock J, Glauser T, Bebin M, Ritter F, Shields DS, Fountain N, Jensen C. Single-dose pharmacokinetics of levetiracetam in pediatric patients with partial epilepsy. 1999 International Epilepsy Congress.
11. Kirby D, Fountain NB., Quigg MS. Utility of a standardized ictal examination. 1999 American Association of Registered EEG Technicians.
12. Gullapalli DN, Fountain NB. Occipital intermittent rhythmic delta activity is associated with epilepsy and not encephalopathy. 1999 American Clinical Neurophysiology Society.
13. Fountain NB, Danesi M, Laws ER, Quigg MS, Bertram, III EH. Sensitivity, positive predictive value, and specificity of MRI, EEG, and Wada tests for outcome from temporal lobectomy. *Epilepsia* 1999;40(Suppl 7);201.
14. Elias J, Laws ER, Bertram EH, Fountain NB. The value of repeat surgery for patients who have failed initial operations for partial complex seizures of temporal lobe origin. *Epilepsia* 1999;40(Suppl 7);220.
15. Frucht M, Quigg MS, Schwaner C, Fountain NB. Sleep and sleep deprivation as seizure precipitants vary with epilepsy syndrome classification. *Epilepsia* 1999;40(Suppl 7):222.
16. Pellock J, Glauser T, Bebin M, Ritter F, Shields DS, Fountain N, Jensen C. Single-dose pharmacokinetics of levetiracetam in pediatric patients with partial epilepsy. *Epilepsia* 1999;40(Suppl 7):124.
17. Fountain NB, French J, Privitera M. Safety and tolerability of harkoseride for refractory partial seizures. *Epilepsia* 2000;41(Suppl 7):169.
18. Schwaner C, Fountain NB. Lifetime incidence of status epilepticus in epileptics. *Epilepsia* 2000;41(Suppl 7):251.
19. Shneker B, Fountain NB. Etiology-specific morbidity and mortality of nonconvulsive status epilepticus. *Epilepsia* 2000;41(Suppl 7):251.
20. Frucht M, Fountain NB, Schwaner C. Antiepileptic drug response of temporal lobe versus extratemporal partial epilepsy. *Epilepsia* 2000;41(Suppl 7):255.
21. Shneker B, Fountain NB. Association between EEG characteristics and mortality in nonconvulsive status epilepticus. 2000 American Clinical Neurophysiology Meeting.
22. Fountain NB, Pellock J, Glauser T, Bebin M, Shields D. Levetiracetam: single dose pharmacokinetics, and open-label efficacy and safety in children with partial onset seizures. 2000 European Congress of Epileptology.
23. Shneker B, Fountain NB. Epilepsy as chronic sequelae following nonconvulsive status epilepticus. *Epilepsia* 2001;42(Suppl 7):147.
24. Waldman WA., Fountain NB, Schwaner C. Differential effects of the menstrual cycle on partial seizures due to temporal lobe epilepsy. *Epilepsia* 2001;42(Suppl 7):267.
25. Fountain NB, Prasad A, Bertram EH, Quigg MS, Laws E. Positive predictive value of presurgical test combinations for good outcome from temporal lobectomy. *Epilepsia* 2001;42(Suppl 7):285.
26. May A, Fountain NB, Schwaner C. Incidence of family history of seizures in patients with classified seizure types and epilepsy syndromes. *Epilepsia* 2001;42(Suppl 7):140-141.
27. Kirby DK, Fountain NB, Quigg MS. Developing new tools for intensive monitoring support staff. American EEG Technologists Annual Meeting, 2002.
28. Epps S, Schwaner C, Waldman W, Fountain NB. Status epilepticus as the first seizure in epilepsy. *Epilepsia* 2002;43(Suppl 7):282.

29. Shneker B, Quigg MS, Fountain NB. Inconsistency of mental status examination when diagnosing nonconvulsive status epilepticus. *Epilepsia* 2002;43(Suppl 7):285.
30. Roehl H, Fountain NB, Bender SD, Mattingly J. Differences in QOLIE-10 in pseudoseizures and epilepsy. *Epilepsia* 2002;43(Suppl 7):96.
31. Sachdeo R, Beydoun A, Hull R, Fountain N, Witt P, Doty P, Rudd D. An open label, dose titration trial to evaluate tolerability and efficacy of oral SPM 927 as adjunctive therapy in patients with partial seizures. *Neurology* 2003;60(Suppl 1):433.
32. Sachdeo R, Montouris G, Beydoun A, Hull R, Fountain N, Doty P, Rudd D, Summerville K. An open label, maximum tolerated dose trial to evaluate oral SPM 927 as adjunctive therapy in patients with partial seizures. 2003 European Federation of Neurological Societies.
33. Kirby D, Quigg MS, Shneker B, Fountain NB. The value of standardized testing in nonconvulsive status diagnosis. *American Journal of Electroneurodiagnostic Technology* 2003;43:241.
34. Fountain NB, Horstmann R, Cawello W Doty P, Rudd GD. Absence of effect of adjunctive SPM 927 on concomitant AED plasma concentrations in subjects with partial seizures. AES 2003.
35. Taft WC, Fountain NB. Long Term Outcome in Lennox-Gastaut Syndrome. AES 2003.
36. Martinez JF, Fountain NB. Frequency of myoclonic seizure exacerbation by lamotrigine in JME. AES 2003.
37. Elias JW, Quigg M, Laws ER, Fountain NB. A comparison of the associated morbidity with intracranial monitoring and resective surgery for extratemporal and temporal lobe epilepsy. AES 2003.
38. Taft WC, Fountain NB. Seizure freedom in Lennox-Gastaut Syndrome. *Epilepsia* 2004;45(Suppl 7):96-97.
39. Ranta A, Fountain NB. Characterization of tumor-related epilepsy. *Epilepsia* 2004;45(Suppl 7):282.
40. Fountain NB, Thompson SR. Long term safety and tolerability of bromides for intractable seizures. *Epilepsia* 2004;45(Suppl 7):132-133.
41. Thompson SR, Palmer B, Fountain NB. Clinical drug study participation improves seizure frequency. *Epilepsia* 2004;45(Suppl 7):144.
42. Martinez JF, Fountain NB. Clinical characteristics of refractory JME. *Epilepsia* 2004;45(Suppl 7):103.
43. Sahoo SK, Goodkin H, Fountain NB. Latency to onset of pseudoseizures. *Epilepsia* 2004;45(Suppl 7):143.
44. Biton V, Rosenfeld WE, Fountain NB, Vaiciene N, Whitesides JG, Sommerville KW. Safety, Tolerability and Pharmacokinetics of Intravenous Lacosamide as Replacement for Oral Lacosamide in Subjects with Partial Seizures. American Academy of Neurology 2005 meeting.
45. Wright CJ, Fountain NB. Reported football related injuries in patients with epilepsy. *Epilepsia* 2005;46(Suppl 8):364.
46. Fountain NB, Liu M. Refractoriness of seizure types and epilepsy syndromes. *Epilepsia* 2005;46(Suppl 8):341.
47. Liu M, Fountain NB. Demographics and AED Use of Seizure Types and Epilepsy Syndromes. *Epilepsia* 2005;46(Suppl 8):348.
48. Liu M, Fountain NB. Rate of seizure freedom in epilepsy. 2006 AES.
49. Fountain NB, Liu M. Ontogeny of seizure freedom. 2006 AES.
50. Guilliams K, Martinez JF, Fountain NB. Physician perceptions of epilepsy in El Salvador. 2006 AES.

51. Lu Z, Fountain NB, Conry JA, Rodríguez-Leyvac I, Gutierrez-Moctezuma J, Salas E, Coupez R, Stockis A. Levetiracetam Pharmacokinetics During Dose Escalation in 4- to 12-Year-Old Children With Partial-Onset Seizures on Concomitant Carbamazepine or Valproate, 2006 AES.
52. Rosenfeld W, Fountain NB, Kaubrys G, Heinzen L, McShea C, and the SP615 Study Team. Lacosamide: an interim evaluation of long-term safety and efficacy as oral adjunctive therapy in subjects with partial-onset seizures. 2007 AES.
53. Elias WJ, Liu M, Fountain NB. Refractoriness of tumor-related epilepsy. AES 2007.
54. Elias J, Sansur C, Frysinger R, Fountain. Risk/Benefit Analysis in the Surgical Treatment of Temporal Lobe Epilepsy. American Association of Neurosurgeons Annual Meeting, 2008.
55. Fountain NB, Liu M. Natural history of seizure patterns in new-onset epilepsy. AES 2008.
56. Fountain NB, Krauss G, Isojarvi J, Dilley D, Doty P. A multicenter, open-label trial to assess the safety and tolerability of a single intravenous loading dose of lacosamide followed by oral maintenance as adjunctive therapy in subjects with partial-onset seizures: an interim report. International Epilepsy Congress 2009.
57. Biton V, Fountain NB, Rosenow F, Gil-Nage A, Sullivan T, Hebert D, Doty P. Safety and Tolerability of Lacosamide: A Summary of Adverse Events in Epilepsy Clinical Trials. AAN 2009.
58. Fountain NB, Krauss G, Isojarvi J, Dilley D, Doty P. A multicenter, open-label trial to assess the safety and tolerability of a single intravenous loading dose of lacosamide followed by oral maintenance as adjunctive therapy in subjects with partial-onset seizures: an interim report. Innsbruck Status Epilepticus Conference 2009.
59. Biton V, Gil-Nage A, Fountain NB, Rosenow F, Hebert D, Doty P. The Safety and Tolerability of Lacosamide as Adjunctive Treatment for Partial-Onset Seizures in Randomized, Double-Blind, Placebo-Controlled Phase II/III Clinical Trials at approved doses. EFNS 2009.
60. VonGaudecker J, Fountain NB. Prevalence of Epilepsy-related Death in an Epilepsy Clinic. AES 2009.
61. Langer J, Tholpady A, Liu M., Fountain NB. Duration of Epilepsy and Occurrence of Status Epilepticus. AES 2009.
62. Fountain NB, Kraus G, Sojarvi J, Dilley D, Doty P. A multicenter, open-label trial to assess the safety and tolerability of a single intravenous loading dose of lacosamide followed by oral maintenance as adjunctive therapy in subjects with partial-onset seizures: an interim report. AES. *Epilepsia* 2009;50(Suppl 11):257-258.
63. Fountain NB, Kraus G, Isojarvi J, Dilley D, Doty P, Rudd GD. A multicenter, open-label trial to assess the safety and tolerability of a single intravenous loading dose of lacosamide followed by oral maintenance as adjunctive therapy in subjects with partial-onset seizures: an interim report. AAN 2010.
64. Fountain NB, Kraus G, Isojarvi J, Dilley D, Doty P, Rudd GD. A multicenter, open-label trial to assess the safety and tolerability of a single intravenous loading dose of lacosamide followed by oral maintenance as adjunctive therapy in patients with partial-onset seizures. ECE 2010.
65. Wong M, Fountain NB. The Frequency of PLEDS as an Ictal Pattern in Nonconvulsive Status Epilepticus, AES 2010.
66. Langer J, Fountain NB. Reliability of status epilepticus coding in the emergency department, AES 2010.
67. Uysal U, Fountain NB. Prospective Analysis of Seizure Frequency in Established Epilepsy. AES 2010.
68. Wicks P, Fountain NB. Patient-reported clinician adherence to epilepsy performance measures of quality care. AAN 2011.

69. Van Ness PC, Fountain NB, Duckrow RB, Gwinn RP, Leiphart JW. Electrographic Events Preceding Sudden Unexplained Death in Epilepsy (SUDEP). AES 2011.
70. Langer JE, Fountain NB. Response of generalized status epilepticus to first, second, and third line therapy. AES 2011.
71. Uysal U, Liu M, Fountain NB. Prospective Analysis of Seizure Freedom in Established Epilepsy. AES 2011.
72. J. Wolfe, S. R. Benbadis, W. O. Tatum, R. P. Turner, A. Arain, N. B. Fountain, S. R. Sinha, P. B. Pritchard, G. U. Martz, E. Kutluay, J. C. Edwards, B. Comparison Of Binary And Ordinal Scoring For Epileptiform Transient Detection. AES 2012.
73. Afeefy H, Uysal U, Fountain NB. Low Prevalence of Mesial Temporal Lobe Epilepsy May Account for Decline in Temporal Lobectomy. AES 2013
74. Langer JE, Fountain NB. Common use but low efficacy of phenytoin for status epilepticus. AES 2013
75. Fountain NB. Potential of Focused Ultrasound in Epilepsy Surgery, : International Symposium on Focused Ultrasound 2014
76. Quigg MS, et al. Interrater reliability in interpretation of electrocorticographic seizure detections of the responsive neurostimulator, AES 2014.
77. Tseng P, Liu M, Fountain NB. Evidence Mesial TLE Is Not Always Medically Refractory, AES 2014

Invited Extramural Lectures:

Potential of Focused Ultrasound for Epilepsy, International Epilepsy Colloquium, Marburg, Germany, May 29, 2014

AED Mechanisms of Action: Are they clinically relevant? AES Pharmacology SIG, Washington DC, December 9, 2013

New and Emerging Therapies for Epilepsy, Pan Arab Union of Neurological Societies, Sharm El Sheikh, Egypt, Feb. 17, 2013

Egyptian Society of Neurology, Neurosurgery, Psychiatry Epilepsy Workshop and Forth Ain Shams University Epilepsy Conference, Cairo, Egypt, October 20-22, 2012:
7 Hour lecture series, "Epilepsy Diagnosis and Treatment"

Refractory Epilepsy in Intellectual and Developmental Delay, Webinar, June 27, 2012

EMU Safety, AES Quality Special Interest Group, Baltimore, December 6, 2011

NAEC Institute of Medicine Survey, NAEC Annual Meeting, December 8, 2011

Epilepsy Quality Performance Measures, Inaugural Epilepsy Symposium, University of Kentucky, Lexington, November 11, 2011

Quality Measures in Neurology and Epilepsy, Ohio State University Neurology Grand Rounds, October 11, 2011

Moderator for ICU Management of Status Epilepticus, 3rd London-Innsbruck Colloquium on Status Epilepticus, Oxford, England, April 8, 2011

Epilepsy Quality Performance Measures and Performance in Practice, American Epilepsy Society SIG, San Antonio, December 5, 2010

Visiting Professor, Anshan Chandga Hospital, Anshan, China, September 20-23, 2010:

- Treatment of Refractory Epilepsy
- Thrombolysis Treatment of Acute Stroke
- Structure of US Medical Education
- Delivery of US Healthcare

Periodic Patterns in ICU Monitoring, Annual Course, American Clinical Neurophysiology Society, San Diego, February 4, 2010

Periodic Discharges and Other Controversial Patterns, AES Plenary Session, Boston, December 5, 2009

Epilepsy Performance Measures, AES Special Interest Group, Boston, December 5, 2009

Recommendation for Women Based on Teratogenic Risk of AEDs, Virginia Neurological Society, Hot Springs, Virginia, February 6, 2009

AAN Epilepsy Quality Measure Development for CMS, Quality Measures SIG, AES Annual Meeting, Seattle, December 9, 2008

Outcome of Nonconvulsive Status Epilepticus, University of Maryland, Neurology Grand Rounds, Oct. 29, 2008

Nonconvulsive Status Epilepticus, Case Western Reserve University, Epilepsy Grand Rounds, July 7, 2008

Visiting Professor, Second Ain Shams University Epilepsy Unit Conference, Cairo, Egypt, October 15-19, 2007:

- AED and Non-Surgical Treatments for Intractable Epilepsy
- Epilepsy Surgery Phase 1: Evaluation: Scalp EEG, Ictal SPECT, MRI, Neuropsych Testing
- Epilepsy Surgery Phase 2: Intracranial Monitoring
- Epilepsy Surgery Phase 3: Resection Methods and Awake Craniotomy
- Outcome from Temporal Lobectomy

New Guidelines in the Treatment of Status Epilepticus, Virginia College of Emergency Physicians Annual Course, Richmond, February 28, 2006

Debate: EEG is an Essential Clinical Tool for Epilepsy (pro). American Epilepsy Society, Washington DC, December 4, 2005

Seizures and Epilepsy, Therapy in Neurology course, American Academy of Neurology, Miami, April 10, 2005

Treatment of Nonconvulsive Status Epilepticus, Status Epilepticus Dinner Seminar, American Academy of Neurology, Miami, April 9, 2005

Pathophysiology and Morbidity of Nonconvulsive Status Epilepticus. Washington University Neurology Grand Rounds, St. Louis, December 15, 2004

Activation of Seizures by Sleep Deprivation, Sleep and Epilepsy Special Interest Group, American Epilepsy Society Meeting, New Orleans, December 5, 2004

Is it Status?, Status Epilepticus Dinner Seminar, American Academy of Neurology, San Francisco, April 25, 2004

Weighing Epilepsy Treatment Options, National Capital CURE Conference, Washington, DC, March 12, 2004

Moderate and case presentations, Difficult Case Discussion Group, Virginia Neurological Society Annual Meeting, Hot Springs, Virginia, February 15, 2004

Practice of Neurology: EEG Cases and Unknowns. Virginia Neurological Society Annual Meeting, Hot Springs, Virginia, February 14, 2004

Clinical Implications of Breakthrough Seizures, Seminar, Society for Neuroscience, New Orleans, November 10, 2003

NCSE: Is it Status?, Status Epilepticus Dinner Seminar, American Academy of Neurology, Honolulu, Hawaii, April 4, 2003

Difficult Management Problems in Patients with Status Epilepticus, Status Epilepticus Dinner Seminar, American Academy of Neurology, Honolulu, Hawaii, April 4, 2003

Status Epilepticus: Advances in Diagnosis and Therapy, Epilepsy Therapy Symposium, American Academy of Neurology, Honolulu, Hawaii, April 2, 2003

Moderate and case presentations, Difficult Case Discussion Group, Virginia Neurological Society Annual Meeting, Hot Springs, Virginia, February 9, 2003

Nonconvulsive Status Epilepticus, Status Epilepticus Dinner Seminar, American Academy of Neurology Annual Meeting, Denver, April 14, 2002

Cortical Physiology: Normal Mechanisms and Epilepsy, American Academy of Clinical Neurophysiology Annual Review Course, Santa Fe, New Mexico, February 15, 2002

Pathophysiology of Status Epilepticus, American Academy of Clinical Neurophysiology Symposium, Santa Fe, New Mexico, February 16, 2002

The Bleeding Edge: Epilepsy Surgery, Virginia Neurological Society Annual Meeting, Hot Springs, Virginia, January 31, 2002

Outcome from Anterior Temporal Lobectomy for Temporal Lobe Epilepsy, George Washington University, Washington D.C., April 12, 2001

Progressive Myoclonic Epilepsy, Virginia Neurological Society Annual Meeting, Hot Springs, Virginia, February 3, 2001

Status Epilepticus: Complications and Treatment, University of Rochester Neurology Grand Rounds, Rochester, New York, November 10, 2000

Clinical Pharmacology of Antiepileptic Drugs, Rochester, New York, November 9, 2000

Complications and Treatment of Status Epilepticus, Merritt-Putnam Lectures on Epilepsy, St. Louis University, Missouri, April 1, 2000

Status epilepticus: risk factors and complications, American Epilepsy Society Annual Course, Orlando, Florida, December 4, 1999

Pathophysiology of epilepsy, Iowa Medical Neurology Association, University of Iowa, Iowa City, Iowa, June 22, 1999

Treatment of Refractory Seizures, Iowa Medical Neurology Association, University of Iowa, Iowa City, Iowa, June 22, 1999

The Role of Entorhinal Cortex in Temporal Lobe Epilepsy, University of Wisconsin Neurology Grand Rounds, Madison Wisconsin, February 1996

Entorhinal Cortex and Epilepsy, University of Kentucky Neurology Grand Rounds, Lexington Kentucky, March 1996

Other Media:

11/1/01 NBC29 TV appearance *House Calls*, "Epilepsy"

11/1/01 *Neurogram* article, "Recent Advances in Epilepsy"

11/18/02 Internet chat sponsored by the Epilepsy Foundation of Virginia

11/24/02 WNRN 91.9 *Wake Up Call* radio show, "Epilepsy Awareness"

11/25/02 UVA-Epilepsy Foundation of Virginia Epilepsy Health Fair lecture, "Epilepsy"

5/23/03 Epilepsy Foundation of Virginia "Nathan B. Fountain Roast and Education Day"

8/31/03 WNRN 91.9 *Wake Up Call* radio show, "Epilepsy Patients Access to Healthcare"

9/03 *Physician's Practice*, interview "Epilepsy Surgery"

6/19/04 ABCNews.com interview, "Seizure Alert Dogs"

11/7/04 WNRN 91.9 *Wake Up Call* radio show, "New Therapies for Epilepsy"

12/7/04 Epilepsy.com interview, "Clinical Drug Study Participation Improves Seizure Frequency"

1/05 *Epilepsy Today* article, "Sleep Deprivation and Epilepsy"
 5/18/05 Epilepsy.com interview, "The Clinical Issues Facing Neurologists Today"
 6/13/05 WINA Radio, "Early Randomized Surgical Epilepsy Trial"
 6/6/05 Epilepsy.com, "University of Virginia Doctors Study Surgery to Stop Epileptic Seizures"
 6/15/05 NBC 29 TV news interview, "Epilepsy Surgery"
 11/3/05 NBC 29 TV news interview, Live at Five, "Epilepsy Awareness"
 2/5/06 NBC 29 TV news citation, "Epilepsy and Football"
 8/20/06 *Fredericksburg Free Lance-Star* citation "Students with medical needs juggle college life"
 10/20/06 WVTM Radio news interview, "UVA Studies new Devices for Epilepsy"
 11/9/06 NBC 29 TV news interview, "Epilepsy Awareness"
 7/13/07 *Physician Practice* interview, "Epilepsy"
 10/31/07 *Neurology*, podcast interview, "Levetiracetam for Idiopathic Generalized Epilepsy"
 11/9/07 NBC 29 TV news interview, "Epilepsy Awareness"
 5/1/08 Epilepsy.com, Hallway Conversations, "Exercise and Epilepsy"
 10/8/08 NBC 29 TV news interview, "New Device to Treat Epilepsy"
 12/3/08 Video Lecture Series, Virginia Emergency Services, "Seizure Emergencies"
 12/7/08 Web interview at TalkAboutIt.org hosted by Greg Grunberg
 2/19/09 Epilepsy.com, Hallway Conversations, "Epilepsy Performance Measures"
 1/23/11 WNRN 91.9 *Wake Up Call* radio show, "Epilepsy"
 4/1/11 MDNG Neurology, "Response to Epilepsy Quality Measures"
 4/12/11 Neurology, podcast interview, "Folic Acid to Prevent Phenytoin Gum Overgrowth"
 10/17/11 The Ictal Zone, "Epilepsy Quality Performance Measures: Pay-For-Performance"
 10/22/11 Neurology Today, "FDA Committee Votes Against Rasagiline As 'Disease Modifying'"
 10/4/12 Neurology Today, "Academy Responds to Demand for National Quality Standards"
 2/27/13 NBC29 TV news interview, "Doctor Explains Disorder After Abduction Charge Dropped"
 7/7/13 NBCnews.com comment, "Teresa Heinz Kerry suffered a grand mal seizure"
 10/22/13 Bridal Tribe interview, "Causes, Management and Treatment of Epilepsy"
 11/13/13 Medscape interview, Alemtuzumab: Mixed Review from FDA Advisory Committee
 12/19/13 Neurology Today interview, FDA Advisory Committee on Alemtuzumab
 12/9/13 MedPage interview, "Satisfaction with Epilepsy Surgery Lasts Long Term"
 1/2/14 Neurology Today interview, "Bio-NanoChips for AED Monitoring"
 2/20/14 Neurology Today interview, "IV Anesthetics for Status Epilepticus"
 3/7/14 The Lancet interview, "FDA's rejection of alemtuzumab divides neurologists"
 4/15/14 Neurology Podcast, "Lesson of the Week: Lacosamide"
 5/23/14 Idaho Public Radio, "Medical Marijuana for Epilepsy"
 6/19/14 Epilepsy.com Podcast, "Epilepsy Quality Measures"
 7/17/14 WMRA radio show, "Medical Marijuana and Dravet Syndrome"
 7/29/14 Medical Law Perspectives, "How are epilepsy and dementia linked?"
 8/26/14 Epilepsy.com/professional podcast, "Epilepsy Monitoring Unit Safety"
 9/3/14 NBC29 PSA, "EFVA Walk"
 11/11/14 Epilepsy.com video interview, "Frequently Asked Questions"
 1/1/15 "FDA reversal sends mixed message to MS community," Nature Reviews Drug Discovery
 3/1/15 Neurology Podcast, "Utilization of AEDs in Pregnant Women in Florida Medicaid"